Dr. Ola Al Ahdab

Dr. Ola Al Ahdab

Ph.D., PGC, RPh, BSC Pharm
Pharmaceutical Advisor-CPD- Pharma Program Manager
Drug Department, Public Health Policy & Licensing
Ministry of Health & Prevention, UAE

Current Designations

  • Pharmaceutical Advisors, Head of Quality Control Section & CPD-Pharma Founder & Program Manager, Drug Department, Ministry of Health & Prevention (MOHAP), United Arab Emirates (UAE)
  • Assistant Professor in Pharmacy Practice (Adjunct faculty), at pharmacy colleges, UAE.
  • Vice-President for Emirates Pharmacy Society (EPS), Emirates Medical Association (EMA)
  • Vice President, Social and Administrative Pharmacy Section (SAPs), International Pharmacy Federation (FIP)
  • Founder & President, ISPOR UAE Chapter

Dr. Al Ahdab is a UAE national working currently as Pharmaceutical Advisor at drug department, Ministry of Health and Prevention, UAE. In addition to her regulatory experience, she hold several positions across the MOH since 1990; such as drug formulary manager, deputy head of procurement, head of the quality and control section, head of inspection and compliance, and head of pharmaceutical care dept. She is an active member on several committees at national, regional and international levels, including, Drug registration, GCC Group Purchase Tendering.

Furthermore, Dr. Al Ahdab is working in Academia since Feb 2009 as adjunct assistant clinical Professor of pharmacy practice for both postgraduates and undergraduates students.

Dr. Ola’s Post graduate studies were completed at Queens University of Belfast, UK, School of Pharmacy, where she was awarded a Ph.D. in Clinical Pharmacy- Medicine Management in December 2008 as a full-time study, and Post Graduate Diploma in Clinical Pharmacy in December 2003 as part-time study. She has completed her undergraduate studies from the Damascus University, School of Pharmacy in Oct 1980.

Research Interests and specialty include and not limited to: Drug regulations& policies, clinical & outcomes research, pricing pharmaceuticals, pharmacoepidemiology, pharmacovigilance, pharmacoeconomics, budget impact analysis, drug utilization reviews, time series analysis, formulary management, efficient procurements, therapeutic tendering, controlling drug expenditure, professional compliance, patient’s safety& adherence to pharmacotherapy initiatives, rational drug use, support training and development, and related studies & research.

As recent achievement, is wining to host FIP congress 2019, from 22-26 Sep in Abu Dhabi, UAE